BridgeBio Pharma Secures $300 Mln For Part Of BEYONTTRA European Royalty Sale
30/6 14:05
(RTTNews) - BridgeBio Pharma, Inc. (BBIO), Monday announced the sale of a certain portion of royalties from sales of BEYONTTRA in Europe to HealthCare Royalty funds managed by Blue Owl Capital for $300 million....